2020
DOI: 10.1111/pai.13332
|View full text |Cite
|
Sign up to set email alerts
|

Compliance, efficacy, and safety of subcutaneous and sublingual immunotherapy in children with allergic rhinitis

Abstract: Allergic rhinitis (AR) is a common clinical problem with the prevalence of 17.6% in the 18 major cities of China and increased gradually, especially in children. 1 Although most patients achieve beneficial effects from medical therapy, allergen immunotherapy (AIT) is the only treatment modality that can alter the natural course of AR. 2

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
34
0

Year Published

2021
2021
2025
2025

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 47 publications
(35 citation statements)
references
References 24 publications
1
34
0
Order By: Relevance
“…AIT can be administrated subcutaneously (SCIT) or sublingually (SLIT), but an increasing number of patients tend to receive SLIT, due to its more convenience and less systemic reactions than those in SCIT ( Li et al, 2018 ; Barker-Tejeda et al, 2020 ). Although SLIT has been demonstrated to be effective in AR, its efficacies differ between patients: some show no benefit even after prolonged treatment ( Liu et al, 2020a ; Zissler and Schmidt-Weber, 2020 ). Previous studies have explored several candidate indicators, such as serum-specific IgE ( Kim et al, 2020 ), periostin ( Hoshino et al, 2020 ), and serum metabolites ( Xie et al, 2021 ), to predict the clinical efficacy of SLIT, but the sensitivity and specificity of these potential biomarkers are not satisfactory.…”
Section: Introductionmentioning
confidence: 99%
“…AIT can be administrated subcutaneously (SCIT) or sublingually (SLIT), but an increasing number of patients tend to receive SLIT, due to its more convenience and less systemic reactions than those in SCIT ( Li et al, 2018 ; Barker-Tejeda et al, 2020 ). Although SLIT has been demonstrated to be effective in AR, its efficacies differ between patients: some show no benefit even after prolonged treatment ( Liu et al, 2020a ; Zissler and Schmidt-Weber, 2020 ). Previous studies have explored several candidate indicators, such as serum-specific IgE ( Kim et al, 2020 ), periostin ( Hoshino et al, 2020 ), and serum metabolites ( Xie et al, 2021 ), to predict the clinical efficacy of SLIT, but the sensitivity and specificity of these potential biomarkers are not satisfactory.…”
Section: Introductionmentioning
confidence: 99%
“…In addition, administration of medicine at home and the lack of regular communication with a physician, who can offer support and encouragement to continue therapy ( 37 ), may also play a role in dropout from SLIT. Dissatisfied with the efficacy is a major reported reason for dropout from SLIT in the current and previous studies ( 24 , 29 , 38 , 39 ). In younger children, refusal or subjective discomfort accounted for dropout in nearly half of the children, and dissatisfaction with the efficacy was rarely reported in younger children ( 40 ), which may be due to the lack of correct perception of the effects.…”
Section: Discussionmentioning
confidence: 51%
“…Market data from two manufacturers in Italy also found there was also a time-dependent increase in discontinuation of SLIT, with a dropout rate of 86.8% by the end of the third year (23). In contrast, a recent prospective study in China observed a much lower dropout rate of 36% at the end of 2 years of SLIT (24). Prospective controlled studies and double-blind, placebocontrolled randomized clinical trials have reported much lower SLIT dropout rates when compared with observational studies (25,26).…”
Section: Discussionmentioning
confidence: 96%
“…It is however accepted that both SLIT application forms are safer than SCIT, in adults and children. 67 In Europe, 8 manufacturers share the market for SCIT and almost equally SLIT products. Only products for sublingual application (SLIT), and insect venom SCIT, 68 are not adjuvanted; for all other SCITs, ready-to-use vials formulated with adjuvants (mostly alum) can be purchased from the industry.…”
Section: Different Ait Practices In the United States And The European Unionmentioning
confidence: 99%